ATE429906T1 - Trockene aripiprazolformulierungen - Google Patents

Trockene aripiprazolformulierungen

Info

Publication number
ATE429906T1
ATE429906T1 AT06251325T AT06251325T ATE429906T1 AT E429906 T1 ATE429906 T1 AT E429906T1 AT 06251325 T AT06251325 T AT 06251325T AT 06251325 T AT06251325 T AT 06251325T AT E429906 T1 ATE429906 T1 AT E429906T1
Authority
AT
Austria
Prior art keywords
dry
aripiprazole formulations
dry aripiprazole
formulations
tablets
Prior art date
Application number
AT06251325T
Other languages
English (en)
Inventor
Julia Hrakovsky
Ruth Tenengauzer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE429906(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE429906T1 publication Critical patent/ATE429906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06251325T 2006-01-05 2006-03-14 Trockene aripiprazolformulierungen ATE429906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75670706P 2006-01-05 2006-01-05

Publications (1)

Publication Number Publication Date
ATE429906T1 true ATE429906T1 (de) 2009-05-15

Family

ID=36617397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06251325T ATE429906T1 (de) 2006-01-05 2006-03-14 Trockene aripiprazolformulierungen

Country Status (13)

Country Link
US (2) US20070154545A1 (de)
EP (1) EP1808165B1 (de)
JP (1) JP2008531738A (de)
CN (1) CN101351193A (de)
AT (1) ATE429906T1 (de)
CA (1) CA2627695A1 (de)
DE (1) DE602006006536D1 (de)
DK (1) DK1808165T3 (de)
ES (1) ES2325219T3 (de)
IL (1) IL190915A0 (de)
PL (1) PL1808165T3 (de)
PT (1) PT1808165E (de)
WO (1) WO2007081367A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200604349A2 (tr) * 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
WO2010079506A2 (en) * 2008-06-23 2010-07-15 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of aripiprazole
CA2773003A1 (en) 2009-09-15 2011-03-24 Ratiopharm Gmbh Orally disintegrating pharmaceutical dosage form containing aripiprazole
TR201000948A1 (tr) * 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
MY163074A (en) * 2010-11-30 2017-08-15 Wista Lab Ltd Formulations comprising methylthioninium chloride
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
JP2016204260A (ja) * 2013-10-04 2016-12-08 日本曹達株式会社 錠剤の製造方法
WO2015067313A1 (en) * 2013-11-07 2015-05-14 Synthon B.V. Orodispersible pharmaceutical compositions comprising aripiprazole
CN106943405B (zh) * 2016-01-06 2021-04-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
KR20190003805A (ko) * 2016-05-27 2019-01-09 한미약품 주식회사 암 세포 성장을 저해하는 아민 유도체 또는 이의 약학적으로 허용가능한 염 및 저융점을 갖는 안정화제를 포함하는 약학적 조성물
CN108014343A (zh) * 2017-12-21 2018-05-11 孟斯琴 一种治疗乳腺癌的药物组合物及其制备方法
CN111213650A (zh) * 2020-02-25 2020-06-02 晋江市老君日化有限责任公司 一种蚊香的制备工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
JP2003238393A (ja) * 2002-02-15 2003-08-27 Otsuka Pharmaceut Co Ltd 施錠性が改善された錠剤及びその製造方法
DE10224170A1 (de) * 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
AU2003230192A1 (en) * 2003-03-21 2004-10-11 Hetero Drugs Limited Novel crystalline forms of aripiprazole
WO2004106322A2 (en) * 2003-04-25 2004-12-09 Cadila Healthcare Limited Polymorphs of aripiprazole
CA2543242C (en) * 2003-10-23 2015-04-14 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile freeze-dried aripiprazole formulation and injectable formulation thereof
EP1613598B1 (de) * 2003-12-16 2011-10-19 Teva Pharmaceutical Industries, Ltd. Verfahren zur herstellung von kristallinen aripiprazolformen
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2006053780A1 (en) * 2004-11-18 2006-05-26 Synthon B.V. Crystalline aripiprazole solvates
EP1812397A1 (de) * 2004-11-18 2007-08-01 Synthon B.V. Verfahren zur herstellung von kristallinem aripiprazol
EP1686117A1 (de) * 2005-01-27 2006-08-02 Sandoz AG Polymorph und Solvate von Aripiprazol
WO2006097344A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
BRPI0611439A2 (pt) * 2005-05-13 2010-09-08 Lexicon Pharmaceuticals Inc compostos multicìclicos e métodos para uso dos mesmos
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
EP1919453A2 (de) * 2005-12-22 2008-05-14 Teva Pharmaceutical Industries Ltd Verfahren zur reduktion der teilchengrösse von aripiprazol
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1880714A1 (de) * 2006-07-20 2008-01-23 Helm AG Amorphes Aripiprazol und Verfahren zu dessen Herstellung

Also Published As

Publication number Publication date
WO2007081367A1 (en) 2007-07-19
HK1104795A1 (en) 2008-01-25
PT1808165E (pt) 2009-06-09
CN101351193A (zh) 2009-01-21
IL190915A0 (en) 2008-11-03
JP2008531738A (ja) 2008-08-14
DK1808165T3 (da) 2009-08-03
PL1808165T3 (pl) 2009-09-30
EP1808165B1 (de) 2009-04-29
ES2325219T3 (es) 2009-08-28
US20070154545A1 (en) 2007-07-05
CA2627695A1 (en) 2007-07-19
DE602006006536D1 (de) 2009-06-10
US20130344146A1 (en) 2013-12-26
EP1808165A1 (de) 2007-07-18

Similar Documents

Publication Publication Date Title
IL190915A0 (en) Dry formulations of aripiprazole
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
ATE528989T1 (de) Kristalline feste rasagilin-base
IL190916A0 (en) Wet granulation pharmaceutical compositions of aripiprazole
EA200802008A1 (ru) Фармацевтические композиции
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
BRPI0913379A2 (pt) formulações farmacêuticas sólidas compreendendo bibw 2992
WO2008057550A3 (en) Stabilization of vaccines by lyophilization
WO2006124748A3 (en) Multicyclic compounds and methods of their use
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
WO2009156462A3 (en) Organic compounds
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
IL204844A (en) Coinolone analogues, pharmaceuticals containing them and their uses
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
GEP20094784B (en) Sustained release pharmaceutical formulations
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
WO2008054808A3 (en) Elvucitabine pharmaceutical compositions
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
PT1810676E (pt) Formulações de levetiracetam e métodos para a sua preparação
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
EA200601596A1 (ru) Улучшенный состав 6-меркаптопурина
WO2006091836A8 (en) Formulations of ladostigil tartrate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties